Intranasal oxytocin as a treatment for chronic pelvic pain: A randomized controlled feasibility study.

Flynn MJ, Campbell TS, Robert M, Nasr-Esfahani M, Rash JA

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics8 Dec 2020Cited by 16 (Europe PMC)

PMID33112417DOI10.1002/ijgo.13441PepBankPUB-33112417

Publisher page PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with chronic pelvic pain, a 2-week course of intranasal oxytocin improved pain severity relative to placebo.
In plain wordsIn women with chronic pelvic pain, two weeks of nasal oxytocin improved pain severity compared with placebo.
Peptide
Oxytocin
Outcome
DecreasePain severity
Study
n = 12
Comparator
Placebo
Outcome group
Pain · Nervous system and cognition
Studied dose
Dose not stated · intranasal · 2 weeksAs given in this study (human).
Source sentences
Summary
Relative to placebo, a 2-week course of oxytocin administration resulted in improvement in pain severity
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the effect of intranasal oxytocin on chronic pelvic pain in a randomized, double-blind, within-subject crossover trial.
Summary · context
Women with chronic pelvic pain were recruited from chronic pain and gynecology clinics between September 2017 and December 2018.
Report a problemFND-3311241701
02HumanRandomized controlled trialEfficacy outcome
In women with chronic pelvic pain, intranasal oxytocin had no effect on pain-related interference relative to placebo.
In plain wordsIn women with chronic pelvic pain, nasal oxytocin did not change how much pain got in the way of life, compared with placebo.
Peptide
Oxytocin
Outcome
No significant changePain-related interference
Study
n = 12
Comparator
Placebo
Outcome group
Pain · Nervous system and cognition
Studied dose
Dose not stated · intranasal · 2 weeksAs given in this study (human).
Source sentences
Summary
with no effect on pain-related interference.
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the effect of intranasal oxytocin on chronic pelvic pain in a randomized, double-blind, within-subject crossover trial.
Summary · context
Women with chronic pelvic pain were recruited from chronic pain and gynecology clinics between September 2017 and December 2018.
Report a problemFND-3311241702
03HumanRandomized controlled trialEfficacy outcome
In women with chronic pelvic pain, four women had a minimal clinically significant improvement in pain after intranasal oxytocin; no women met this threshold with placebo.
In plain wordsFour women with chronic pelvic pain had a clinically meaningful pain improvement after nasal oxytocin. None did with placebo.
Peptide
Oxytocin
Outcome
IncreaseMinimal clinically significant improvement in pain (responders)
Study
n = 12
Comparator
Placebo
Outcome group
Pain · Nervous system and cognition
Studied dose
Dose not stated · intranasal · 2 weeksAs given in this study (human).
Source sentences
Summary
This effect was driven by four women who demonstrated a minimal clinically significant improvement in pain following intranasal oxytocin (no women met this threshold for placebo).
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the effect of intranasal oxytocin on chronic pelvic pain in a randomized, double-blind, within-subject crossover trial.
Summary · context
Women with chronic pelvic pain were recruited from chronic pain and gynecology clinics between September 2017 and December 2018.
Report a problemFND-3311241703
04HumanRandomized controlled trialSafety outcome
In women with chronic pelvic pain, adverse effects did not differ between intranasal oxytocin and placebo.
In plain wordsIn women with chronic pelvic pain, side effects of nasal oxytocin were not different from those with placebo.
Peptide
Oxytocin
Outcome
No significant changeAdverse effects
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · intranasal · 2 weeksAs given in this study (human).
Source sentences
Summary
occurrence of adverse effects did not differ between oxytocin and placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the effect of intranasal oxytocin on chronic pelvic pain in a randomized, double-blind, within-subject crossover trial.
Summary · context
Women with chronic pelvic pain were recruited from chronic pain and gynecology clinics between September 2017 and December 2018.
Report a problemFND-3311241704
05HumanRandomized controlled trialOther
In women with chronic pelvic pain, adherence to intranasal oxytocin dosing was excellent.
In plain wordsIn women with chronic pelvic pain, people took nasal oxytocin as planned.
Peptide
Oxytocin
Outcome
Not applicableAdherence to dosing
Study
n: not reported in source
Comparator
Placebo
Outcome group
Treatment adherence and retention · Whole body
Studied dose
Dose not stated · intranasal · 2 weeksAs given in this study (human).
Source sentences
Summary
Adherence to dosing was excellent
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the effect of intranasal oxytocin on chronic pelvic pain in a randomized, double-blind, within-subject crossover trial.
Summary · context
Women with chronic pelvic pain were recruited from chronic pain and gynecology clinics between September 2017 and December 2018.
Report a problemFND-3311241705

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2/3NCT02888574

Evaluating the Efficacy of Intranasal Oxytocin Among Individuals With Persistent Pain

University of Calgaryn = 24Nov 2016 to Dec 2018

Chronic Pain · Pelvic Pain

Trial page ClinicalTrials.govUpdated 18 May 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 02:48 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.